Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results
Por:
Eron, J, Margolis, D, Gonzalez-Garcia, J, Stellbrink, HJ, Yazdanpanah, Y, Podzamczer, D, Lutz, T, Angel, JB, Richmond, GJ, Clotet, B, Gutierrez, F, Sloan, L, Sutton, KC, Dorey, D, Smith, KY, Williams, PE and Spreen, WR
Publicada:
1 jul 2017
Resumen:
Filiaciones:
Eron, J:
Univ North Carolina Chapel Hill, Div Infect Dis, Chapel Hill, NC USA
Margolis, D:
ViiV Healthcare, Res Triangle Pk, NC USA
Gonzalez-Garcia, J:
Hosp Univ La Paz, IdiPAZ, Madrid, Spain
Stellbrink, HJ:
ICH Hamburg, Hamburg, Germany
Yazdanpanah, Y:
Hop Bichat Claude Bernard, Paris, France
Podzamczer, D:
Ciudad Sanitaria Univ Bellvitge, Barcelona, Spain
Lutz, T:
Infektiologikum, Frankfurt, Germany
Angel, JB:
Ottawa Hosp, Ottawa, ON, Canada
Richmond, GJ:
Broward Gen Med Ctr, Ft Lauderdale, FL USA
:
UAB, UVIC UCC, Hosp Germans Trias & Pujol, Badalona, Spain
Gutierrez, F:
Hosp Gen Elche, Alicante, Spain
Univ Miguel Hernandez, Alicante, Spain
Sloan, L:
North Texas Infect Dis Consultants, Dallas, TX USA
Sutton, KC:
ViiV Healthcare, Res Triangle Pk, NC USA
Dorey, D:
GlaxoSmithKline, Mississauga, ON, Canada
Smith, KY:
ViiV Healthcare, Res Triangle Pk, NC USA
Williams, PE:
Janssen Res & Dev, Beerse, Belgium
Spreen, WR:
ViiV Healthcare, Res Triangle Pk, NC USA
|